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A B S T R A C T 
Objective: To examine the impact of the 21-gene 
Oncotype DX Breast Cancer Assay on the adjuvant 
treatment decision-making process for early-stage 
breast cancer in Hong Kong.
Design: Retrospective study.
Setting: Private hospital, Hong Kong.
Patients: Study included cases of early-stage breast 
cancer (T1-2N0-1M0, oestrogen receptor–positive, 
human epidermal growth factor receptor 2–
negative) that were presented at a multidisciplinary 
breast meeting at a single site. Cases were selected for 
Oncotype DX testing with the assistance of Adjuvant! 
Online. The recommendations for adjuvant therapy 
before and after obtaining the Oncotype DX 
Recurrence Score results were analysed.
Results: A total of 154 cases that met the inclusion 
criteria were discussed at our multidisciplinary 
breast meeting. Of these, 64 cases with no clear 
recommendation by the Meeting Panel were selected 
for this study and reviewed. The distribution of 
Recurrence Score results was similar to that reported 
by others, with a somewhat higher proportion of low 
Recurrence Scores. Treatment recommendation was 
changed for 20 (31%) patients after the Oncotype 
DX result was received. Of the changes in treatment 
decisions, 16 (80%) were changes to lower-intensity 
regimens (either equipoise or hormonal therapy). 
Initial experience with the Oncotype DX assay 
in decision-making for adjuvant therapy of early 
oestrogen receptor–positive breast cancer in 
Hong Kong
Introduction
Breast cancer is the most common cancer among 
women in Hong Kong, with an incidence of 54.8 
per 100 000 population in 2010.1 Over the past two 
decades, breast cancer incidence in Hong Kong 
has been trending upward, from a lifetime risk of 
1 in 27 women in 2000 to a lifetime risk of 1 in 19 
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Implications for clinical practice or policy
• The Oncotype DX Breast Cancer Assay can assist in making definitive treatment recommendations.
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women in 2010. As a result, Hong Kong now has 
an intermediate-to-high breast cancer incidence 
compared with other Asian countries. The median 
age of diagnosis of breast cancer is 53 years. Early-
stage breast cancer (ESBC; defined as stages 0 to II) 
is most common at diagnosis, accounting for 81.3% 
of cases.2 The most common stage at diagnosis is 
ORIGINAL ARTICLE
The number of cases receiving an equipoise 
recommendation decreased by nine (82%), based on 
the additional information provided by the Oncotype 
DX test.
Conclusion: The Oncotype DX Recurrence Score 
information impacts the decision-making process 
for adjuvant therapy for early-stage breast cancer 
in the multidisciplinary care setting in Hong Kong. 
A larger-scale study is required to gain more 
experience, evaluate its impact more thoroughly, 
and assess its cost-effectiveness.
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Oncotype DX 測試對香港早期ER+乳腺癌輔助
療法的決策過程的初步經驗
張淑儀、唐治、梁澄宇、關永康、 邱宗祥
目的：探討21-基因Oncotype DX乳腺癌分析對香港早期乳腺癌輔助治
療決策程序的影響。
設計：回顧研究。
安排：香港一所私家醫院。
患者：在一個研究站點的多科會診中提交的早期乳腺癌（T1-2N0-
1M0、ER+、HER2-）病例中，挑選部分接受Oncotype DX測試及 
Adjuvant! Online輔助治療的病例。對在收到Oncotype DX復發指數結
果前和後的輔助療法建議進行分析。
結果：共154份符合入選標準的病例，其中沒有明確會診建議的64份
病例入選本研究並接受審查。復發指數結果的分佈與其他機構公佈
的結果相似，惟低復發指數所佔比例略高。在收到Oncotype DX結果
後，對20名患者（31%）的治療建議作出修改。在被修改的治療決
策中，有16例（80%）改為低強度方案（不明確或激素治療）。基於 
Oncotype DX測試提供的額外資料，接受不明確建議的病例數量減少9
人（82%）。
結論： Oncotype DX 復發指數資料對香港多科團隊進行輔助療法決策
的過程產生了影響。需要進行更大範圍的研究及積累更多經驗，以更
全面評估Oncotype DX乳腺癌分析的影響力及其成本效益。
stage II (39.7%).2
 Among those diagnosed with ESBC in Hong 
Kong, 98% undergo surgery, 62% receive adjuvant 
chemotherapy, and 66% receive hormonal therapy 
(HT). Adjuvant therapy has been shown to increase 
survival,3 which includes HT, chemotherapy, or 
both. The decision to administer adjuvant therapy 
depends on clinical, pathological, and histochemical 
features of the tumour, which influence the risk 
of recurrence.4,5 At our institution, it has been the 
practice since 2003 to discuss all breast cancer cases 
at the multidisciplinary breast meeting (MDM) prior 
to making adjuvant treatment recommendations. In 
this model, cases are submitted for weekly review 
by a group of health care professionals including 
surgeons, oncologists, pathologists, and experts from 
other disciplines who can add value to optimising 
the treatment plan for each patient.
 The Oncotype DX Breast Cancer Assay 
(Oncotype DX; Genomic Health, Inc, Redwood City 
[CA], US) has been validated to measure the risk 
of recurrence in patients with oestrogen receptor–
positive (ER+), human epidermal growth factor 
receptor 2–negative (HER2-), and lymph node 
negative  tumours. The Oncotype DX test analysed 
21 genes and generated a Recurrence Score which 
is used to quantify the likelihood of distant disease 
recurrence at 10 years post-treatment. For prognostic 
use, the Recurrence Score value is categorised into 
low- (<18), intermediate- (18-30), and high-risk (>30) 
groups. Typically, patients receiving a low Recurrence 
Score result will receive HT in the absence of other 
factors that increase the risk of recurrence. Patients 
receiving high scores have a higher risk of recurrence 
and are more likely to respond to chemotherapy; 
therefore, these patients often receive a combination 
of chemotherapy followed by HT. The appropriate 
therapy for patients with an intermediate score 
is the subject of ongoing clinical trials. Several 
prospective studies have validated its prognostic and 
predictive significance using data from the NSABP-
B14, NSABP-20, and SWOG 8814 trials.6,7 Oncotype 
DX has now been incorporated into the National 
Comprehensive Cancer Network and the St Gallen 
guidelines for use.4,5
 Significant toxicity and cost can accrue to 
patients undergoing adjuvant chemotherapy, but 
only a small proportion experience survival benefits. 
The Recurrence Score result can be used to assess the 
10-year risk of recurrence and the potential benefit 
from adjuvant chemotherapy and, thereby, assist in 
development of a treatment plan that makes optimal 
use of resources for the patient’s benefit.
 The aim of this study was to examine the 
impact of the additional information provided by 
the Oncotype DX test on the clinical treatment 
decisions for patients diagnosed with ESBC. The 
study compared treatment regimens proposed by 
a multidisciplinary breast cancer team before and 
after receipt of the Oncotype DX results.
Methods
Study design
This single-centre study was conducted at the Hong 
Kong Sanatorium and Hospital, a private institution 
in Hong Kong. This study was a retrospective 
review of patients with breast cancer who had 
surgery between 2008 and 2011, whose cases had 
been reviewed by the MDM, and who had received 
Oncotype DX assay testing to obtain additional 
information on recurrence risk. Recurrence risk 
was assessed by the MDM using clinical factors 
(including age, tumour size, number of positive 
lymph nodes, and grade) and Adjuvant! Online,8 and 
a provisional treatment recommendation was made. 
The Oncotype DX test was ordered after the MDM to 
obtain additional recurrence risk information when 
there was a difference of opinion on interpretation 
of available information. The test was not ordered 
when a consensus of opinion on treatment 
recommendation was reached. Cost of testing was 
borne by insurance or the patient. For each case, the 
MDM made final treatment recommendations after 
consideration of the Recurrence Score results; the 
#  Oncotype DX decision impact in Hong Kong  # 
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actual treatment received took into account patient 
preference, and might have differed from that 
recommended by the MDM. Eligible patients had 
ESBC (T1-2N0-1M0 tumours) that was determined 
to be ER+, HER2-, and with at most one positive 
lymph node. In addition, the patient profile was 
consistent with that prescribed by international 
guidelines for application of this assessment.4,5 
The Recurrence Score result was discussed for all 
patients and a recommendation was made by simple 
majority of opinion. Therapy recommendations 
before Recurrence Score result were categorised as 
chemohormonal therapy (CHT), equipoise where a 
clear recommendation for either CHT or HT was 
not possible, or HT. Changes in intensity of therapy 
were categorised as increased intensity from HT to 
equipoise or CHT and equipoise to CHT; changes 
were categorised as decreased intensity for changes 
from CHT to equipoise or HT and equipoise to HT.
Statistical analysis
Data were summarised by using descriptive statistics. 
For cases considered in this study, the distribution 
of parameter values in the sample was described 
by calculating the mean, median, and range where 
appropriate.
Results
During the study period from 1 August 2008 to 
30 June 2011, a total of 620 breast cancer patients 
with T1-2N0-1M0 tumours underwent surgery. 
Among them, 154 were ER+ HER2- cases. A total 
of 66 cases for which there was no unanimity in 
the MDM were reviewed, of which 64 fulfilled the 
inclusion criteria for this study; two cases were 
excluded because HER2 status was determined to 
be overexpressed by immunohistochemistry. The 
tumours were predominantly grade II (63%) and 
similar proportions were stage IA (42%) and stage 
IIA (48%), with small number of stage IIB cases (9%) 
[Table 1]. Nine patients with positive lymph nodes 
(N1 or N1a) were included in the study based on 
clinical and pathological assessments suggesting 
less-aggressive disease.
 The Recurrence Score values were categorised 
as low- (<18), intermediate- (18-30), and high-
risk (>30) according to the Oncotype DX assay 
recommendation which gave an estimated distant 
recurrence rate after the use of HT alone. The 
panel discussed the possible benefit of adding 
chemotherapy to the treatment regimen for each 
patient to reach a consensus recommendation 
specific for the patient. In this study, the majority 
of patients had a low-risk Recurrence Score (64%) 
whilst patients with intermediate- and high-risk 
Recurrence Score values were less frequent (30% and 
6%, respectively). The distribution of Recurrence 
Score results by tumour stage is shown in Table 2. 
In this cohort, the distribution of Recurrence Score 
results by stage was similar to the overall distribution 
of the Recurrence Score results. Stage IA tumours 
were comprised of 63% low and 26% intermediate 
Recurrence Score results, while stage IIA tumours 
were comprised of 68% low and 29% intermediate 
Recurrence Score results. Stage IIB tumours were 
evenly split between low and intermediate scores.
 The specific changes in treatment 
recommendations for all patients in the study 
are shown in Table 3. Overall, the treatment 
recommendations for 20 (31%) of the 64 patients 
changed intensity when the Recurrence Score result 
was considered. The changes in treatment decisions 
were predominantly to HT (14/20; 70% of changed 
treatment recommendations) for the entire cohort. 
Other changes included two recommendations (10% 
of changed recommendations) that were changed 
from CHT to equipoise and four (20%) which 
resulted in a higher-intensity CHT recommendation 
over HT or equipoise. Interestingly, five of six stage 
TABLE 1.  Patient and tumour characteristics (n=64)
Characteristic No. (%) of cases*
Patient age (years)
Mean 48
Range 24-67
Tumour size (cm)
Mean 2.28
Median 2.05
Range 0.60-7.20
Tumour grade
Grade I 18 (28)
Grade II 40 (63)
Grade III 6 (9)
Tumour stage†
IA 27 (42)
IIA 31 (48)
IIB 6 (9)
*	 Or	as	otherwise	stated
†	 %	may	not	total	100	because	of	rounding
TABLE 2.  Distribution of Recurrence Score by stage
Stage No. (%)
Low Intermediate High Total
IA 17 (63) 7 (26) 3 (11) 27 (100)
IIA 21 (68) 9 (29) 1 (3) 31 (100)
IIB 3 (50) 3 (50) 0 (0) 6 (100)
Total 41 (64) 19 (30) 4 (6) 64 (100)
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IIB cases received CHT recommendations both pre– 
and post–Recurrence Score result. In the sixth stage 
IIB case, a patient with lobular carcinoma staged as 
T3N0M0 with a Recurrence Score result of 8, the 
treatment recommendation was changed from CHT 
to HT upon receipt of the score.
 The distribution of treatment recommen-
dations by stage before and after Oncotype DX 
testing is shown in Table 3. For stage I patients, 
recommendations were changed in eight (30%) of 27 
patients, while for stage II patients recommendations 
were changed in 12 (32%) of 37 patients. As for the 
entire cohort, the changes in treatment decisions 
were predominantly to HT for both stage I (5/8, 
63%) and stage II (9/12, 75%) patients. In the stage 
I tumours, all four equipoise recommendations 
(15% of recommendations prior to Oncotype DX 
testing) were changed after testing. The proportion 
of CHT recommendations remained the same at 13 
(48%) and HT recommendations increased from 10 
(37%) to 14 (52%) after receipt of the Recurrence 
Score result. In stage II tumours, the proportion 
receiving recommendations for equipoise decreased 
from 7 (19%) to 2 (5%). The CHT recommendations 
decreased somewhat from 26 (70%) to 22 (59%), while 
the proportion receiving a HT recommendation 
increased from 4 (11%) to 13 (35%).
 The distribution of Recurrence Score categories 
by therapy recommendation before and after receipt 
of Oncotype DX results is shown in the Figure. The 
number of low Recurrence Score cases in the CHT 
group decreased from 20 before Recurrence Score 
information to 13 after the Recurrence Score result 
was obtained, while the number of low Recurrence 
Score cases in the group that did not require 
chemotherapy increased from 21 to 28 once the 
Recurrence Score information was available. While 
two patients in the high Recurrence Score group 
did not receive a recommendation for CHT pre–
Oncotype DX, all the cases with high Recurrence 
Scores received a recommendation for CHT post–
Oncotype DX.
Discussion
This first analysis of the impact of the Oncotype DX 
Breast Cancer Assay on adjuvant treatment for early-
breast cancer in Hong Kong revealed similarities 
with studies in other populations worldwide with 
regard to the distribution of Recurrence Score 
results, proportion of treatment recommendations 
that changed upon consideration of Oncotype 
DX information, and shift in proportions of 
chemotherapy recommendations compared with 
other treatment recommendations.9-13
 The Recurrence Score distribution observed 
in this retrospectively selected cohort of breast 
cancer patients is similar to that observed in other 
studies of ESBC, with predominance of lower 
Recurrence Score values. These results are also 
comparable to the Asia-Pacific region’s Recurrence 
Score distribution reported by Genomic Health: 
low risk=51%, intermediate risk=33%, and high 
risk=16%.14 The distribution observed in this study 
differed from other studies9,12,13 in that the proportion 
Abbreviations:	CHT	=	chemohormonal	therapy;	HT	=	hormonal	therapy
TABLE 3.  Changes in treatment recommendation
Pre–Recurrence 
Score
Post–Recurrence Score recommendation, 
No. (%)
Row total, 
No. (%)
CHT Equipoise HT
Stage I
CHT 10 (77) 0 3 (23) 13 (48)
Equipoise 2 (50) 0 2 (50) 4 (15)
HT 1 (10) 0 9 (90) 10 (37)
Subtotal 13 (48) 0 14 (52) 27 (100)
Stage II
CHT 21 (81) 2 (8) 3 (12) 26 (70)
Equipoise 1 (14) 0 6 (86) 7 (19)
HT 0 0 4 (100) 4 (11)
Subtotal 22 (59) 2 (5) 13 (35) 37 (100)
Overall
CHT 31 (79) 2 (5) 6 (15) 39 (61)
Equipoise 3 (27) 0 8 (73) 11 (17)
HT 1 (7) 0 13 (93) 14 (22)
Total 35 (55) 2 (3) 27 (42) 64 (100)
FIG.  Distribution of Recurrence Score groups by treatment recommendation 
pre– and post–Oncotype DX test
The	cases	were	categorised	by	therapy	recommendation	pre–Oncotype DX testing 
(pre-HT,	pre-EQ,	pre-CHT)	and	the	same	cases	were	re-categorised	by	therapy	
recommendation	post–Oncotype	DX	testing	(post-HT,	post-EQ,	post-CHT)
Abbreviations:	CHT	=	chemohormonal	therapy;	EQ	=	equipoise;	HT	=	hormonal	
therapy
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of low Recurrence Score results was higher and the 
proportion of high Recurrence Score results was 
lower than previously observed. Since these cases 
were estimated to derive borderline benefit based 
on their initial assessment using Adjuvant! Online 
and clinical parameters, it might be expected that 
Recurrence Score distribution in this cohort would 
be skewed at the lower end as well. When examined 
by stage, the Recurrence Score distribution did 
not change substantially. In fact, all six stage IIB 
tumours had low or intermediate Recurrence 
Scores, including the single T3 tumour in this study. 
This observation is consistent with that in other 
studies9,15,16 showing that the Recurrence Score assay 
provides information not inherent to traditional 
clinicopathological assessments of the tumour.
 Inclusion of Oncotype DX information led to 
a change in 20 (31%) of 64 treatment plans. These 
results correspond with similar decision impact 
studies from the US,12,13,17 European Union,9,10 
and the Middle East11 that assessed the impact of 
Recurrence Score information on choice of adjuvant 
therapy in ESBC. The proportion of treatment plans 
that changed in these studies ranged from 25% to 
40%, so the 30% observed in this study is typical.
 The proportion of changes to CHT or in 
the other direction to HT as a result of Oncotype 
DX testing in breast cancer is also similar to that 
in other studies, with the proportion of CHT 
recommendations decreasing and the proportion of 
HT recommendations increasing.9-13 Changes were 
largely to lower-intensity treatments, with 80% of the 
20 changed recommendations shifting from CHT 
or equipoise to a lower-intensity regimen. Most 
of these transitions to lower-intensity treatment 
recommendations resulted from movement of the 
equipoise cases to HT (40% of changes). An additional 
30% of the changes were shifts from CHT to HT 
recommendations. This effect was seen with the only 
T3 tumour in the study, classified as T3N0M0, a case 
which transitioned from a CHT recommendation to 
HT after receiving a low-risk Recurrence Score of 8. 
Recurrence Score information resulted in increases 
in treatment intensity as well. The two cases with 
a high score that were not originally given a CHT 
recommendation were switched to CHT after 
consideration of the Recurrence Score.
 Adjuvant treatment for ESBC is an important, 
yet complex area faced by oncologists. To patients, 
this is a life-changing decision, the outcome of 
which will drastically impact their lives. The 
decision whether to give chemotherapy as part 
of adjuvant therapy to cancer patients can be 
difficult with traditional prognostic indicators 
as, often, they have been insufficient to identify 
patients who will benefit from those who may not 
benefit. A number of prognostic tools have been 
developed, including Oncotype DX and Adjuvant! 
Online that can aid the multidisciplinary team 
in making decisions on adjuvant treatment. The 
additional information provided by the Oncotype 
DX Recurrence Score result provides the physician 
with unique information in the assessment of risk 
of recurrence. In this study, cases were selected that 
were deemed to have intermediate risk using clinical 
factors and Adjuvant! Online, and for which there 
was no unanimous agreement. This was exemplified 
by inclusion of nine lymph node–positive cases. 
Their disease was considered less aggressive based 
on assessment of the tumour biology, creating 
uncertainty about the necessity of chemotherapy 
for these patients. Thus, the Oncotype DX test was 
recommended so that the multidisciplinary team 
would have additional information on which they 
could base their adjuvant treatment decisions. 
Given the high proportion of ESBC cases in Hong 
Kong, such cases may be frequent and there is an 
evident need for Oncotype DX testing to assist in 
making treatment recommendations. The additional 
information gained can help physicians and patients 
avoid expensive and toxic chemotherapy.
 Limitations of the study were its retrospective 
nature. In addition, selection of patients was 
non-uniform; cases were selected based on their 
intermediate-risk assessment in MDMs; and the 
selected cases were the ones for which the physicians 
had difficulty in making treatment recommendations.
Conclusion
This study demonstrated that the distribution 
of Oncotype DX Recurrence Score results in the 
population of women with ESBC in Hong Kong 
is similar to that reported in other geographical 
regions in the world. The impact of the Recurrence 
Score information on adjuvant treatment decisions 
in Hong Kong was also similar to that reported by 
others, with the main effect being a shift in treatment 
recommendations to lower-intensity regimens. 
Finally, the proportion of equipoise chemotherapy 
recommendations was greatly reduced, suggesting 
that the Recurrence Score can assist in making 
definitive treatment recommendations in cases 
for which physicians are ambivalent about using 
chemotherapy.
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